TABLE 2.
GMCs and 95% CIs of serum specimens from noncases, RICs, cRICs, and pRICS stratified according to timing of serum collection
| Daysb | Noncasesa |
RICs |
cRICs |
pRICs |
||||
|---|---|---|---|---|---|---|---|---|
| No. of samples | GMCc (95% CI) | No. of samples | GMC (95% CI) | No. of samples | GMC (95% CI) | No. of samples | GMC (95% CI) | |
| 0–2 | 12 | 1,322 (674–2,593) | 36 | 5,214 (2,884–9,429) | 5 | 105,714 (43,932–248,686) | 3 | 1,904 (1,573–2,102) |
| 3–4 | 4 | 2,859 (1,838–4,553) | 16 | 52,819 (24,570–113,551) | 4 | 136,888 (68,906–177,788) | 3 | 157,012 (102,871–193,883) |
| 5–7 | 9 | 1,838 (741–4,553) | 21 | 102,163 (68,788–151,732) | 2 | 197,124 (156,289–248,628) | 3 | 200,993 (187,189–208,590) |
| 8–42 | 13 | 951 (478–1,895) | 15 | 57,485 (23,022–143,537) | 11 | 130,350 (61,547–206,580) | 2 | 55,924 (47,986–65,176) |
a
PRN assay-determined measles neutralizing antibody concentrations identified as outliers were excluded.
b
Days are after rash onset.
c
The GMCs were calculated for concentrations of measles neutralizing antibodies measured in mIU/ml.